Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine and Oral Fluid Drug Testing for Federal Agencies, 83953-83955 [2023-26428]
Download as PDF
<![CDATA[
83953
Federal Register / Vol. 88, No. 230 / Friday, December 1, 2023 / Notices
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, NIH has
submitted to OMB a request for review
and approval of the information
collection listed below.
Proposed Collection Title: Assurance
(Interinstitutional, Foreign, and
Domestic) and Annual Report, OMB
#0925–0765, expiration date 11/30/
2022, Reinstatement with Change,
Office of the Director (OD), National
Institutes of Health (NIH).
Need and Use of Information
Collection: The NIH Office of Laboratory
Welfare (OLAW) is responsible for the
implementation, general administration,
and interpretation of the Public Health
Service (PHS) Policy on Humane Care
and Use of Laboratory Animals (Policy)
as codified in 42 CFR 52.8. The PHS
Policy implements the Health Research
Extension Act (HREA) of 1985 (Pub. L.
99–158 as codified in 42 U.S.C. 289d).
The PHS Policy requires entities that
conduct research involving vertebrate
animals using PHS funds to have an
Institutional Animal Care and Use
Committee (IACUC), provide assurance
that requirements of the Policy are met,
and submit an annual report.
Institutions in foreign countries comply
with the PHS Policy or provide
evidence that acceptable standards for
the humane care and use of the animals
in PHS-conducted or -supported
activities will be met. An institution’s
animal care and use program is
described in the Animal Welfare
Assurance (Assurance) document and
sets forth institutional compliance with
PHS Policy. The purpose of the
Assurance (Interinstitutional, Foreign,
and Domestic) and Annual Report is to
provide OLAW with documentation to
satisfy the requirements of the HREA,
illustrate institutional adherence to PHS
Policy, and enable OLAW to carry out
its mission to ensure the humane care
and use of animals in PHS-supported
research, testing, and training, thereby
contributing to the quality of PHSsupported activities.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours are
9,219.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Average
burden per
response
(in hours)
Total annual
burden hours
Type of respondents
Domestic Assurance ...................................................................................
Domestic Annual Report .............................................................................
Foreign Assurance ......................................................................................
Foreign Annual Report ...............................................................................
Interinstitutional Assurance for Foreign Performance Site or Interinstitutional Assurance Triad for Foreign Performance Site.
Interinstitutional Assurance for Domestic Performance Site or Interinstitutional Assurance Triad for Domestic Performance Site.
Renewal and New .......
All Domestic .................
Renewal and New .......
All Foreign ....................
Foreign .........................
235
890
67
335
46
1
1
1
1
1
30
90/60
90/60
1
30/60
7,050
1,335
101
335
23
Domestic ......................
750
1
30/60
375
Total .....................................................................................................
......................................
2,323
6
....................
9,219
Dated: November 22, 2023.
Lawrence A. Tabak,
Principal Deputy Director, National Institutes
of Health.
[FR Doc. 2023–26400 Filed 11–30–23; 8:45 am]
BILLING CODE 4140–01–P
location will stay the same. The meeting
is closed to the public.
Dated: November 27, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–26451 Filed 11–30–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
lotter on DSK11XQN23PROD with NOTICES1
Number of
responses per
respondent
Form name
BILLING CODE 4140–01–P
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
National Institutes of Health
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Initial Review Group; Career
Development Study Section (J),
February 28, 2024, 10:00 a.m. to
February 29, 2024, 06:00 p.m., National
Cancer Institute Shady Grove, 9609
Medical Center Drive, Room 7W624,
Rockville, Maryland 20850 which was
published in the Federal Register on
November 2, 2023, FR Doc. 2023–24225,
88 FR 75294.
This notice is being amended to
change the start time of the meeting
from 10:00 a.m. to 9:00 a.m. on February
28, 2024. The meeting dates and
18:47 Nov 30, 2023
Jkt 262001
Dated: November 28, 2023.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2023–26450 Filed 11–30–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
VerDate Sep<11>2014
meeting to December 14, 2023, and
December 15, 2023. The meeting time
remains the same. The meeting is closed
to the public.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Neurological
Disorders and Stroke; Amended Notice
of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Neurological Disorders and Stroke
Special Emphasis Panel, November 27,
2023, 10:00 a.m. to November 28, 2023,
05:00 p.m., National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 which
was published in the Federal Register
on November 13, 2023, FR Doc 2023–
24961, 88 FR 77597.
This notice is being amended to
change the dates of this two-day
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
SUMMARY:
E:\FR\FM\01DEN1.SGM
01DEN1
lotter on DSK11XQN23PROD with NOTICES1
83954
Federal Register / Vol. 88, No. 230 / Friday, December 1, 2023 / Notices
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs using Urine or Oral Fluid
(Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT:
Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Flanagan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: In
accordance with Section 9.19 of the
Mandatory Guidelines, a notice listing
all currently HHS-certified laboratories
and IITFs is published in the Federal
Register during the first week of each
month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
The Department of Health and Human
Services (HHS) notifies Federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
of the laboratories currently certified to
meet the standards of the Mandatory
Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020.
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
VerDate Sep<11>2014
18:47 Nov 30, 2023
Jkt 262001
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for Federal
agencies. HHS does not allow IITFs to
conduct oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines using Urine and/
or Oral Fluid. An HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that the test facility has met minimum
standards. HHS does not allow IITFs to
conduct oral fluid testing.
HHS-Certified Laboratories Approved
To Conduct Oral Fluid Drug Testing
In accordance with the Mandatory
Guidelines using Oral Fluid dated
October 25, 2019 (84 FR 57554), the
following HHS-certified laboratories
meet the minimum standards to conduct
drug and specimen validity tests on oral
fluid specimens:
At this time, there are no laboratories
certified to conduct drug and specimen
validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial
Testing Facilities Approved To Conduct
Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine dated January
23, 2017 (82 FR 7920), the following
HHS-certified IITFs meet the minimum
standards to conduct drug and specimen
validity tests on urine specimens:
Dynacare,* 6628 50th Street NW,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories)
HHS-Certified Laboratories Approved
To Conduct Urine Drug Testing
In accordance with the Mandatory
Guidelines using Urine dated January
23, 2017 (82 FR 7920), the following
HHS-certified laboratories meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917
Desert Tox, LLC, 5425 E Bell Rd, Suite
125, Scottsdale, AZ 85254, 602–457–
5411/623–748–5045
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890
Dynacare,* 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630, (Formerly: GammaDynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.)
Laboratory Corporation of America,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295,
(Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group)
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339, (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center)
MedTox Laboratories, Inc., 402 W
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
E:\FR\FM\01DEN1.SGM
01DEN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 230 / Friday, December 1, 2023 / Notices
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088. Testing for Veterans Affairs
(VA) Employees Only
Omega Laboratories, Inc.,* 2150
Dunwin Drive, Unit 1 & 2,
Mississauga, ON, Canada L5L 5M8,
289–919–3188
Pacific Toxicology Laboratories, 9348
DeSoto Ave., Chatsworth, CA 91311,
800–328–6942, (Formerly: Centinela
Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation
Drive, San Diego, CA 92128, 888–
635–5840
Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403,
610–631–4600/877–642–2216,
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline BioScience Laboratories)
US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235, 301–677–7085. Testing for
Department of Defense (DoD)
Employees Only
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (61 FR 37015,
July 16, 1996) as meeting the minimum
standards of the Mandatory Guidelines
published in the Federal Register on
January 23, 2017 (82 FR 7920). After
receiving DOT certification, the
laboratory will be included in the
monthly list of HHS-certified
laboratories and participate in the NLCP
certification maintenance program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace
Programs.
[FR Doc. 2023–26428 Filed 11–30–23; 8:45 am]
BILLING CODE 4160–20–P
VerDate Sep<11>2014
18:47 Nov 30, 2023
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: 988 Cooperative
Agreements Monitoring Program (OMB
No. 0930–0290)—New ICR
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) is seeking Office of
Management and Budget (OMB)
Emergency approval for new
information collection activities for
monitoring all of SAMHSA’s 988
Cooperative Agreements. The collection
of this information is critical to
successfully oversee operational
response and quality of service through
the 988 Suicide and Crisis Lifeline to
ensure connections to care for
individuals in suicidal crisis or
emotional distress contacting in for 988
phone, chat, and text support for
connecting local, state/territory and
national outcomes and monitoring
contractual obligations for current and
future 988 grant programs. Much of this
information is already embedded in the
current 988 Suicide and Crisis Lifeline
network administrator grants, the 988
state and territory grant program, or the
988 Tribal Response grant program.
Congress designated 988 in 2020 and
the Lifeline transitioned to the 3-digit
number in July 2022. As a part of the
federal government’s commitment to
addressing the mental health crisis in
America, unprecedented federal
resources have been invested to scale up
crisis centers in support of 988. In
section 1103(a)(2)(B) of the
Consolidated Appropriations Act, 2023,
Congress called for enhanced program
evaluation, including performance
measures to assess program response
and improve readiness and performance
of the service, including review of each
contact to ensure timely connection of
service and quality provision in line
with evidence-based care. To help meet
the standards and requirements set forth
in statute, ongoing communication of
key outcomes within this OMB request
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
83955
must be received and reviewed to
ensure connection and quality of care
through 988.
The information being collected will
be used by SAMHSA to ensure
individuals in suicidal crisis can contact
988 Suicide and Crisis Lifeline and are
connected to crisis centers provided
evidence-based care and able to receive
critical resource referral and linkage,
including opportunities for mobile crisis
support, crisis receiving and stabilizing
facilities, peer respite centers and
withdrawal management services. The
four programs to be monitored and
evaluated include the Tribal
Cooperative Agreements, State and
Territory Cooperative Agreements, 988
Crises Center Follow-up Cooperative
Agreements, and the 988 Lifeline
Administrator.
The purpose of the Tribal Cooperative
Agreements is to provide resources to
improve response to 988 contacts
(including calls, chats, and texts)
originating in Tribal communities and/
or activated by American Indians/
Alaska Natives. The information
collection instruments include Tribal
Government: Semi Annual Progress
Report, Tribal Government: Monthly
Meeting Agenda, Tribal Government:
Quality Improvement Plan.
The purpose of the State and Territory
Cooperative Agreements is to improve
state and territory response to 988
contacts (including calls, chats, and
texts) originating in the state/territory.
The information collection instruments
include State/Territory: Monthly Key
Metrics, State/Territory: Quarterly
Report Template, State/Territory:
Programmatic QI Plan (Annual
Collection), State/Territory: Monthly
Meeting Call Agenda, State/Territory:
Chat and Text Report (Annual
Collection), State/Territory:
Communications Plan (Annual
Collection), State/Territory:
Sustainability Plan (Annual Collection),
State/Territory: Mobile Crisis and 988–
911 reports (Annual Collection).
The purpose of the 988 Crisis Center
Follow Up Cooperative Agreements is to
provide a crisis center response that
ensures the systematic follow-up of
suicidal persons who contact a 988
Suicide and Crisis Lifeline (988 Lifeline)
Crisis Center; provides enhanced
coordination of crisis stabilization,
crisis respite, mobile crisis outreach
(MCO) response services and other
services on the crisis continuum of care;
reduces unnecessary police engagement
and; improves connections for high-risk
populations. The information collection
instruments include Crisis Center Data
Reporting Elements and Crisis Center
Monthly Agenda Template.
E:\FR\FM\01DEN1.SGM
01DEN1
]]>Agencies
[Federal Register Volume 88, Number 230 (Friday, December 1, 2023)]
[Notices]
[Pages 83953-83955]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-26428]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine and Oral Fluid Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
Federal agencies of the laboratories and Instrumented Initial Testing
Facilities
[[Page 83954]]
(IITFs) currently certified to meet the standards of the Mandatory
Guidelines for Federal Workplace Drug Testing Programs using Urine or
Oral Fluid (Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT: Anastasia Flanagan, Division of
Workplace Programs, SAMHSA/CSAP, 5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240-276-2600 (voice);
[email protected] (email).
SUPPLEMENTARY INFORMATION: In accordance with Section 9.19 of the
Mandatory Guidelines, a notice listing all currently HHS-certified
laboratories and IITFs is published in the Federal Register during the
first week of each month. If any laboratory or IITF certification is
suspended or revoked, the laboratory or IITF will be omitted from
subsequent lists until such time as it is restored to full
certification under the Mandatory Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the internet at https://www.samhsa.gov/workplace/resources/drug-testing/certified-lab-list.
The Department of Health and Human Services (HHS) notifies Federal
agencies of the laboratories and Instrumented Initial Testing
Facilities (IITFs) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and of the laboratories currently
certified to meet the standards of the Mandatory Guidelines using Oral
Fluid.
The Mandatory Guidelines using Urine were first published in the
Federal Register on April 11, 1988 (53 FR 11970), and subsequently
revised in the Federal Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January 23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral Fluid were first published in
the Federal Register on October 25, 2019 (84 FR 57554) with an
effective date of January 1, 2020.
The Mandatory Guidelines were initially developed in accordance
with Executive Order 12564 and section 503 of Public Law 100-71 and
allowed urine drug testing only. The Mandatory Guidelines using Urine
have since been revised, and new Mandatory Guidelines allowing for oral
fluid drug testing have been published. The Mandatory Guidelines
require strict standards that laboratories and IITFs must meet in order
to conduct drug and specimen validity tests on specimens for Federal
agencies. HHS does not allow IITFs to conduct oral fluid testing.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines using Urine and/or Oral Fluid. An HHS-
certified laboratory or IITF must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA), which attests that the test facility
has met minimum standards. HHS does not allow IITFs to conduct oral
fluid testing.
HHS-Certified Laboratories Approved To Conduct Oral Fluid Drug Testing
In accordance with the Mandatory Guidelines using Oral Fluid dated
October 25, 2019 (84 FR 57554), the following HHS-certified
laboratories meet the minimum standards to conduct drug and specimen
validity tests on oral fluid specimens:
At this time, there are no laboratories certified to conduct drug
and specimen validity tests on oral fluid specimens.
HHS-Certified Instrumented Initial Testing Facilities Approved To
Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine dated
January 23, 2017 (82 FR 7920), the following HHS-certified IITFs meet
the minimum standards to conduct drug and specimen validity tests on
urine specimens:
Dynacare,* 6628 50th Street NW, Edmonton, AB Canada T6B 2N7, 780-784-
1190, (Formerly: Gamma-Dynacare Medical Laboratories)
HHS-Certified Laboratories Approved To Conduct Urine Drug Testing
In accordance with the Mandatory Guidelines using Urine dated
January 23, 2017 (82 FR 7920), the following HHS-certified laboratories
meet the minimum standards to conduct drug and specimen validity tests
on urine specimens:
Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504-361-
8989/800-433-3823, (Formerly: Kroll Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.)
Alere Toxicology Services, 450 Southlake Blvd., Richmond, VA 23236,
804-378-9130, (Formerly: Kroll Laboratory Specialists, Inc., Scientific
Testing Laboratories, Inc.; Kroll Scientific Testing Laboratories,
Inc.)
Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS
66215-2802, 800-445-6917
Desert Tox, LLC, 5425 E Bell Rd, Suite 125, Scottsdale, AZ 85254, 602-
457-5411/623-748-5045
DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800-
235-4890
Dynacare,* 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-
1630, (Formerly: Gamma-Dynacare Medical Laboratories)
ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655,
662-236-2609
LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS
66219, 913-888-3927/800-873-8845, (Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division
of LabOne, Inc.)
Laboratory Corporation of America, 1225 NE 2nd Ave., Portland, OR
97232, 503-413-5295/800-950-5295, (Formerly: Legacy Laboratory Services
Toxicology MetroLab)
Laboratory Corporation of America Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713-856-8288/800-800-2387
Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America Holdings, 1904 TW Alexander Drive,
Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly:
LabCorp Occupational Testing Services, Inc., CompuChem Laboratories,
Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical
Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche
Group)
Laboratory Corporation of America Holdings, 1120 Main Street,
Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp
Occupational Testing Services, Inc.; MedExpress/National Laboratory
Center)
MedTox Laboratories, Inc., 402 W County Road D, St. Paul, MN 55112,
651-636-7466/800-832-3244
Minneapolis Veterans Affairs Medical Center, Forensic Toxicology
[[Page 83955]]
Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
Testing for Veterans Affairs (VA) Employees Only
Omega Laboratories, Inc.,* 2150 Dunwin Drive, Unit 1 & 2, Mississauga,
ON, Canada L5L 5M8, 289-919-3188
Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA
91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology
Laboratory)
Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888-635-
5840
Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403,
610-631-4600/877-642-2216, (Formerly: SmithKline Beecham Clinical
Laboratories; SmithKline Bio-Science Laboratories)
US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755-5235, 301-677-7085. Testing for
Department of Defense (DoD) Employees Only
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the certification of
those accredited Canadian laboratories will continue under DOT
authority. The responsibility for conducting quarterly performance
testing plus periodic on-site inspections of those LAPSA-accredited
laboratories was transferred to the U.S. HHS, with the HHS' NLCP
contractor continuing to have an active role in the performance testing
and laboratory inspection processes. Other Canadian laboratories
wishing to be considered for the NLCP may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (61 FR 37015, July 16, 1996)
as meeting the minimum standards of the Mandatory Guidelines published
in the Federal Register on January 23, 2017 (82 FR 7920). After
receiving DOT certification, the laboratory will be included in the
monthly list of HHS-certified laboratories and participate in the NLCP
certification maintenance program.
Anastasia D. Flanagan,
Public Health Advisor, Division of Workplace Programs.
[FR Doc. 2023-26428 Filed 11-30-23; 8:45 am]
BILLING CODE 4160-20-P
